8th Annual

HPAPI Summit

June 19-21, 2019 The Westin Boston Waltham

www.hpapi-summit.com

"THIS CONFERENCE IS A CLEAR LEADER IN THE HPAPI ARENA"

Pfizer

Enabling Robust, Safe and Cost-Effective Production of Highly Potent APIs

David Eherts
Vice President, Global EHS
Allergan

Andy Brewer
Principal Engineer, Global Biologics MSAT
Genentech

John Roosa
Associate Director & Industrial Hygiene Engineering, **Merck**

Ben English
EHS Program Specialist
Nektar Therapeutics

Sarah Jones
Senior Manager, Occupational Hygiene
Pfizer

Senior Partners

ILC DOVER

SK biotek

amri
Complex Science. Expert Solutions.

ChargePoint TECHNOLOGY

Lonza

Delivered By:

hansonwade

+1 617 455 4188 info@hansonwade.com HPAPI Summit

WELCOME
TO THE INDUSTRY-LEADING HIGHLY POTENT API EVENT

Uniting The Entire Highly Potent Drug Development Value Chain - From Bench To Point Of Outsource

ABOUT US

In the context of ever-increasing drug potency, the 8th Annual HPAPI Summit is devoted to providing the insights required to improve the efficiency, safety and cost-effectiveness of HPAPI production.

This meeting will bring together perspectives from process engineers, EHS and industrial hygiene leaders to break down communication barriers and build a harmonized approach that will increase safety and effectiveness at every stage of development.

Focusing specifically on the unique challenges involved in working with HPAPIs, this conference will provide real-world case-studies from the companies actively working on these compounds, enabling you to implement safe and robust practices in your own organization.

Incorporating insights from **Genentech, Pfizer, Boehringer Ingelheim, SafeBridge** and **AbbVie,** you will leave this conference with actionable insights that will enable you to produce highly potent APIs more robustly, safely and cost-effectively.

BRAND NEW CONTENT

Explore How Established Facilities Need to Adapt to Handle Unique Potent Compounds

Understand the cross-contamination controls, analytics and novel regulatory strategy that were required when **Genentech** introduced a novel high potency bispecific to a shared commercial facility. This in-depth case study will enable you to learn how to successfully navigate the introduction of highly potent compounds into your own facilities.

Assess the ROI of EHS Strategies to Build the Business Case for Containment

Examine the processes that can be employed to calculate the return on investment of various EHS approaches. As well as providing a realistic break-down of investment vs return, this presentation will detail how these calculations resulted in fundamental changes in the relationship between EHS and **Allergan's** leadership.

Maintain Effective Containment Throughout Scale-Up

Investigate containment approaches for handling potent compounds at the lab scale, as well as understanding how containment needs change at processes scale. Insights from **Boehringer Ingelheim** will enable you to set in place robust and scalable processes, as well as implementing appropriate containment strategies at every scale.

"THIS CONFERENCE CAN SERVE AS BOTH AN INCUBATOR AND CATALYST TO EDUCATE AND HARMONIZE ACROSS THE INDUSTRY."

Seattle Genetics

YOUR EXPERT SPEAKERS

Marc Abromovitz
Head, Industrial Hygiene
Novartis

Rich Arnett
Manager, Industrial Hygiene
Pharmascience

Andy Brewer
Principal Engineer, Global Biologics MSAT
Genentech

Jack Brown
Senior Research Fellow
Boehringer Ingelheim

Jay Brown
Senior EHSS Specialist
Alkermes

David Eherts
Vice President, Global EHS
Allergan

Ben English
EHS Program Specialist
Nektar Therapeutics

Joseph Fruehbrodt
Senior Specialist, EHS
AbbVie

William Goundry
Associate Principal Scientist
AstraZeneca

Abizer Harianawala
Senior Director, Product Development and Technical Operations
TARIS Biomedical

Maurits Janssen
Senior Director, Head of Commercial Development, **Lonza**

Marco Jonas
Associate Research Fellow, Process Development, **AMRI**

Sarah Jones
Senior Manager, Occupational Hygiene
Pfizer

Jason Korbel
Technical Services Manager
Cambrex

Sanga Mutah
Validation Engineer
Genentech

Scott Patterson
VP, Commercial Sales
ILC Dover

Mike Rasmussen
Pilot Plant Operations Manager
AbbVie

James Ratway
Associate Director, Pharmaceutical Development
AbbVie

Chris Rombach
Head of North American Sales
ChargePoint Technology

John Roosa
Associate Director & Industrial Hygiene Engineering, **Merck**

Claudio Salvagnini
Sales Director
Minakem

Bob Sussman
Managing Director
SafeBridge

Anthony Toto
Senior Director, Process Engineering
TESARO

Patricia Weideman
President & Principal
Sakari Consultants

Speaker To Be Confirmed
SK Biotek

WHO WILL YOU MEET?

IMPROVING INDUSTRY HARMONIZATION THROUGHOUT THE VALUE CHAIN

Evidently, there is a lack of communication and alignment between key members of the HPAPI development chain, causing inefficiencies and hampering the progress of the field. To combat this, the HPAPI Summit will unite **perspectives of stakeholders at every stage of HPAPI production,** breaking down these siloes and allowing you to gain a comprehensive insight into the development of potent compounds.

Interactive sessions built into the main agenda provide extensive opportunities for cross-functional collaboration. Whether you are approaching this field as a large or small drug developer, CMO or containment company, this event will enable you to benchmark your progress and critically evaluate your approach to dealing with highly potent compounds. Leave the event with **actionable insights that will drive efficiency, guarantee safety and ensure cost-effectiveness** in all of your HPAPI development programs.

PREVIOUS ATTENDEES INCLUDE

abbvie, Aegerion Pharmaceuticals, alcami, amri, ARIAD, Biogen, BioVectra, Boehringer Ingelheim, Bristol-Myers Squibb, büchiglasuste, ILC DOVER, Eisai, Lilly, EVONIK, Genentech, GILEAD, Hovione, IMMUNOGEN, INC., IPSEN, MERCK, Mallinckrodt, MERRIMACK, Mersana, NOVARTIS, Pfizer, REGENERON, Roche, SafeBridge, SANOFI, SeattleGenetics, Takeda, VERTEX

GAIN PERSPECTIVES FROM EVERY STAGE OF DEVELOPMENT:

- **Process Chemist**
- **Process Engineer**
- **Occupational Toxicologist**
- **EHS Professional**
- **Tech Transfer**
- **Industrial Hygienist**
- **Outsourcing Manager**
- **Procurement Specialist**

PRE-CONFERENCE MEET & GREET

Join us for a relaxed drink on the evening before the main conference gets underway. Use this as an opportunity to forge new relationships and rekindle existing ones in an informal, relaxed environment, before the main conference starts.

Drinks will be available and you will also be able to pre-register for the conference.

PRE-CONFERENCE WORKSHOP DAY
WEDNESDAY, JUNE 19

WORKSHOP A 8:00am – 11:00am

Strategies for Successfully Scaling-Up Highly Potent Compounds

Maintaining quality as well as safety at every scale is a major consideration when developing potent compounds. Whatever your experience in this field is, this workshop will provide you with actionable insights to improve the effectiveness of your scale-up strategy, first by analyzing the current best-practice potent compound scale-up, then diving deep into a case study detailing the scale-up of ADC payload production.

Attendees will discuss:

- The scale-up landscape through a structured literature review
- Approaches to balance speed, quality, cost and safety throughout scale-up
- Case study – what to consider when scaling-up the synthesis of ADC payloads

WORKSHOP LEADER:

William Goundry
Associate Principal Scientist
AstraZeneca

WORKSHOP B 11:30am – 2:30pm

Developing Effective Potent Compound Training Procedures

The most state of the art containment technologies and facilities need adequately and appropriately trained operators to ensure safety as well as effectiveness. This workshop will discuss the specific elements that make training in this field successful, as well as approaches to share and disseminate this information throughout organizations and beyond.

Attendees will discuss:

- Ensuring operators are trained sufficiently to understand complex and new systems
- Establishing expectations around the handling of potent compounds
- Implementing approaches to measure the effectiveness of training to demonstrate effectiveness

WORKSHOP LEADER:

Jay Brown
Senior EHSS Specialist
Alkermes

WORKSHOP C 3.00pm - 6.00pm

Outsourcing the Development and Manufacture of HPAPIs: Perspectives from the CMOs and Drug Innovators

This workshop will identify the importance of the relationship between the Drug Innovator and the Contract Manufacturing Organization (CMO). Drug innovators need the confidence that their CMOs understand the potential hazards of the drug substances they are handling in order to deliver the product on time and within spec. At the same time, CMOs need to insist that a robust assessment of the occupational and product safety concerns is documented so they can understand how these substances must be handled. This session will provide a general overview of the roles and responsibilities of the parties involved in this partnership and will identify many of the elements that a Drug Innovator should look for in a CMO (and vice versa). Attendees will discuss:

- Methods for evaluating the hazard of drug substances
- How exposure potential is evaluated in the workplace
- Communication between the Drug Innovator and CMO
- Management's role

WORKSHOP LEADER:

Bob Sussman
Managing Director
Safebridge

6:00pm Pre-Conference Meet & Greet

CONFERENCE DAY ONE THURSDAY, JUNE 20

7:30 **Registration, Coffee & Networking**

Bob Sussman
Managing Director
Safebridge

8:20 **Chair's Opening Remarks**

INVESTIGATING STRATEGIES TO HANDLE INNOVATIVE POTENT COMPOUNDS

Andy Brewer
Senior Principal Engineer, Global Biologics Manufacturing Science and Technology
Genentech

Sanga Mutah
Validation Engineer
Genentech

8:30 **Introduction of a High Potency Bi-Specific Antibody to a Multi-Product, Shared Clinical and Commercial Biotech Facility - A Case Study**

- A unique challenge for an established facility requiring:
  - Enhanced personnel protection and handling controls
  - Additional cross-contamination controls to address the risk to other products
  - The rapid development of sensitive product-specific analytics
  - A novel regulatory filing strategy and pre-introduction guidance from Health Agencies
  - Close collaboration between diverse departments: QC, Analytical Development, Engineering, Occupational Toxicology, Manufacturing, Quality, Validation and Regulatory
- Successes, lessons-learned, and improvements for future Hi-Potent product introductions

Maurits Janssen
Senior Director, Head of Commercial Development
Lonza

9:00 **HPAPI Best Practices: Requirements for Fully-Integrated Service-Offerings in a HPAPI & Cytotoxic Environment**

Drug product development based on potent compounds can be quite challenging. Complications with the interface between operations in drug substance and drug product handling can also result in increased program complexity and cost. In this presentation, we will elaborate on best practices and infrastructure requirements that facilitate accelerated timelines to clinic and market:

- CASE STUDY: the development, rapid scaling and commercial production of HPAPI drug substance
- Integrated containment requirements for particle engineering and drug products
- Impact of supporting integrated service-offerings on expansion strategies

9:30 **Speed Networking & Morning Refreshments**

SUCCESSFULLY CONTAINING AND DEVELOPING HPAPIS AT EVERY SCALE

Rich Arnett
Manager, Industrial Hygiene
Pharmascience

10:45 **Maintaining Effective Containment Through Scale Up in a Generics Environment**

- Understanding how containment needs change as processes scale, backed up by IH data
- Identifying and overcoming equipment challenges
- Successfully utilizing disposable equipment to maintain safety and cost-effectiveness

Jack Brown
Senior Research Fellow
Boehringer Ingelheim

11:15 **Successfully Containing and Developing HPAPIs at Lab Through to Pilot Plant Scale & Beyond**

- Establishing robust and scalable procedures early in development
- Overcoming unexpected containment challenges encountered in the scale-up of potent compounds
- Case studies investigating the establishment of procedures for handling HPAPIs in early stage development work

SK Biotek
Speaker to be Confirmed

11:45 **Operation of a Fully Integrated & Versatile HPAPI Manufacturing Facility**

- Effective containment design strategy for handling HPAPIs from g to kg
- IH monitoring philosophy
- Purification strategy for HPAPIs SK Biotek

12:15 **Networking Lunch**

CONFERENCE DAY ONE THURSDAY, JUNE 20

Marco Jonas
Associate Research Fellow, Process Development
AMRI

1:45 **Process Safety Assessment in an High Potency Environment**

- Process safety testing vs. HP requirements - overcoming challenges
- Dust explosion assessment for potent compounds
- Calorimetry for potent compounds

James Ratway
Associate Director, Pharmaceutical Development
AbbVie

2:15 **Lessons Learnt from the Establishment of New Engineering Standards for Potent Compounds**

- Understanding the key decision points navigated in the establishment of new engineering standards
- Establishing risk-based primary and secondary containment standards applicable from lab all the way through to full-scale manufacturing
- Case study: Exploring the design of new potent compound facilities

Jason Korbel
Technical Services Manager
Cambrex

2:45 **Design of a Mid-Scale HPAPI Commercial Facility**

- Using risk based assessment to develop occupational exposure limits
- Challenges of design and operation of a multi-purpose HPAPI facility
- Containment strategies utilized for maintaining flexibility

3:00 **Afternoon Refreshments & Networking**

UTILIZING DATA-DRIVEN RISK MANAGEMENT APPROACHES

Marc Abromovitz
Head, Industrial Hygiene
Novartis

3:30 **Applying a Risk Based Approach for Defining Exposure Controls in the Workplace**

- The OEL and band are not the only criteria for selecting exposure controls
- The value proposition for applying risk based data driven decision-making for exposure controls
- The dose makes the poison

Michael Rasmussen
Senior Chemist, TechOps
AbbVie

Joseph Fruehbrodt
Senior EHS Specialist
Abbvie

4:00 **Deep Dive: Enabling Containment Technologies**

- Background
  - Drug Linker Syntheses and pipeline focus in late 2016
  - Fear and misunderstanding of toxicity/handling requirements/engineering controls
  - HPAPI Facility Design Phase identifies high aerosol risk unit operations of typical processes to be conducted in isolators
  - Pipeline needs still need to be supported until completion of facility – IH Studies conducted for lowest exposure targets to determine if flexible containment technologies can meet process containment needs
  - IH monitoring program philosophy (when surrogate monitoring is executed, value back to the business)
- Unit operations investigated in IH Studies
  - Description of equipment and operational challenges
  - Description of how IH experiments designed to represent actual processes (technician, IH, Tech Ops collaboration)
  - Description of unit operation studied
- IH Results of Individual Unit Operations
  - Description of monitoring methodologies
  - Sample locations/intervals
  - Data analysis and interpretation (trends from operational causes)
  - Conclusions and recommendations moving forward

Bob Sussman
Managing Director
Safebridge

5:00 **Chair's Closing Remarks**

5:15 **End of Conference Day 1**

Evening Social Event in Central Boston

After the formal presentations have finished, digest the full day of content with your fellow delegates at our evening social event.

Transport will be provided. Tickets will be made available to registered delegates at a later date.

CONFERENCE DAY TWO FRIDAY, JUNE 21

Patricia Weideman
President & Principal
Sakari Consultants

8:20 **Chair's Opening Remarks:**

David Eherts
Vice President, Global EHS
Allergan

8:30 **Keynote: The Value of Containment**

- Presenting the Return-on-HSE-Investment process to calculate ROI, NPV, DPP, IUC
- Examining details of the capital and ERC costs of containment equipment and installations vs the savings associated with eliminating open handling or LEV solutions
- Discussing the resulting changes in relationships with executive leadership

IMPLEMENTING ROBUST, DATA-DRIVEN CONTAINMENT STRATEGIES

John Roosa
Associate Director, New Technology Development and Industrial Hygiene Engineering, ***Merck***

9:00 **A Hands-On Investigation of Potent Compound Handling Techniques**

- Understanding and mitigating against common failures of techniques
- Examining the pitfalls of industrial handling techniques and investigating strategies to improve processes
- Sharing best-practices to maintain safety and containment

Scott Patterson
VP, Commercial Sales
ILC Dover

9:30 **Safe Handling of HPAPI in Development and Scale-Up Manufacturing**

- Risk assessment for HPAPI handling in pre-clinical development
- Value analysis of single use technology vs. rigid systems
- Effectiveness of Open isolators vs. Closed isolators
- Case study for dispensing HPAPI and OSD processes
- Scale up Manufacturing for HPAPI dispensing

Scott Patterson
VP, Commercial Sales
ILC Dover

John Roosa
Associate Director, New Technology Development and Industrial Hygiene Engineering, ***Merck***

10:00 **Interactive Panel Discussion: Cross-Disciplinary Perspectives on Innovative Containment Strategies & Their Implementation**

This interactive panel session will enable you to participate in a discussion around the value of a variety of containment approaches. Voice your opinion and interact with the experts on issues such as:

- Investigating the situations in which flexible and disposable containment systems can add the most value
- What levels of containment can be reached by flexible facilities?
- Strategies to clean flexible containment systems – investigating innovative approaches to enable more effective and efficient cleaning

10:45 **Morning Refreshments & Networking**

Chris Rombach
Head of North American Sales
ChargePoint Technology

11:15 **Protecting Your People and Your Products: Aseptic Transfer of Potent Compounds**

- Current approaches; benefits and limitations
- Reducing HVAC requirements through engineered transfer design
- Retrofitting existing processes
- VHP capabilities, implementation and management

DESIGNING & USING FACILITIES TO SUCCESSFULLY CONTAIN POTENT COMPOUNDS

Ben English
EH&S Program Specialist
Nektar Therapeutics

11:45 **From "One-Off" Projects to Control by Design: One Company's HPAPI Evolution**

- EH&S and IH assessment and control strategies for short-term/ limited scope high-potency API (HPAPI*) manufacturing in areas not specifically designed for HPAPI work
- Designing an API pilot plant to control HPAPI materials
- Planning for construction of a HPAPI pilot plant without disrupting other GMP manufacturing operations

*Nektar's definition of HPAPI is to a lower limit of 30 ng/m3 for the purpose of this presentation

CONFERENCE DAY TWO FRIDAY, JUNE 21

Claudio Salvagnini
Sales Director
Minakem

12:15 **Minakem: A Fully Integrated HPAPI CDMO**

- 40+ years' experience in development and manufacturing of High Potent ingredients
- New state of the art R&D high containment lab for handling HPAPI with OEL below 0,1 mg/m3
- GMP production from grams to hundreds kg per batch
- Integrated supply chain for non-HP and non GMP intermediates and starting material

12:30 **Lunch & Networking**

Sarah Jones
Senior Manager, Global Environmental Health and Safety, Occupational Hygiene
Pfizer

1:30 **Exposure Data-Driven Guidance for Laboratory Handling of Potent Compounds**

- Is current engineering guidance adequate when working with highly hazardous compounds in R&D labs?
- Lessons learned relating to containment performance of lab equipment and employee work practices
- Communicating good and bad news to a science based community

David Eherts
Vice President, Global EHS
Allergan

Marc Abromovitz
Head, Industrial Hygiene
Novartis

2:00 **Speaker Debate: What's the Best Approach to Potent Compound Containment?**

This interactive session will provide an opportunity to witness a point-counterpoint debate between two experts in the field with differing opinions on the best ways to approach potent compound assessment and containment

2:30 **Afternoon Refreshments & Networking**

IMPLEMENTING SUCCESSFUL OUTSOURCING STRATEGIES

Abizer Harianawala
Senior Director, Product Development and Technical Operations
TARIS Biomedical

3:00 **Facilitating Robust and Safe Outsourcing Procedures**

- Establishing mutually-beneficial and sustainable partnerships throughout the full life cycle of potent compound development
- Understanding the aspects that need to be aligned both at the business and technical level
- Evaluating the key criteria used to assess contract development and manufacturing organizations in the highly potent space

Anthony Toto
Senior Director, Process Engineering
TESARO

3:30 **Presentation Details to Be Confirmed**

Patricia Weideman
President & Principal
Sakari Consultants

4:00 **Chair's Closing Remarks**

4:15 **Close of HPAPI Summit 2019**

"The conference was excellent! It's a great way to network with other individuals facing the same challenges and learn from those who have already gone through them."

Vertex

"I learned a lot, got a chance to benchmark with other colleagues and the networking sessions were wonderful. I would definitely attend again."

Gilead

PARTNERSHIP OPPORTUNITIES

Are you front of mind when pharma and biotech outsource manufacturing and make procurement decisions?

Drug developers have told us they lack visibility on which CMOs and containment equipment providers have the expertise and experience, as well as technology and facilities required to guarantee the robust, safe and cost-effective development of highly potent APIs.

Partner with the 8th Annual HPAPI Summit to demonstrate that you have the capabilities to meet the increasing demands of this emerging field.

2019 Partners

PROGRAM PARTNER

ILC Dover

DoverPac® Containment Systems, an ILC Dover brand, is the global pioneer of dis posable process and powder containment systems. Launched from a partnership with multi-national pharmaceutical companies to develop high containment for API production and oral sold dosage processing, DoverPac® is the global standard for containment, reliability, and service.

www.ilcdover.com/about-doverpac-containment-systems

PROGRAM PARTNER

SK Biotek

SK Biotek is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. SK Biotek is known for its presence in custom chemical development, advanced intermediates and Active Pharmaceutical Ingredients (API, HPAPI) manufacturing. SK Biotek is a leader in continuous process technology leveraging knowhow in catalytic hydrogenation, low temperature reactions just to name a few.

www.skbiotek.com

PROGRAM PARTNER

AMRI

AMRI is a global contract research and manufacturing organization, working with the Life Sciences industry to improve patient outcomes and the quality of life for more twenty-five years. AMRI's API Manufacturing business supports chemical development through cGMP manufacture of a diverse range of complex Active Pharmaceutical Ingredients (APIs), including steroids and hormones.

www.amriglobal.com

PROGRAM PARTNER

ChargePoint Technology

ChargePoint Technology is the market leader in powder containment and aseptic transfer valves providing operator safety and sterility assurance for the pharmaceutical, biotech, chemical and other process industries.

ChargePoint Technology manufacturers its cutting-edge devices in its multi-million pound purpose built facility in Liverpool, UK, employs more than 70 employees across the globe and secured a multi-million pound investment from LDC, part of Lloyds Banking Group in January 2017, to meet the increase in global demand for its products and solutions.

www.thechargepoint.com

PARTNERSHIP OPPORTUNITIES

PROGRAM PARTNER

Lonza

Lonza Pharma & Biotech provide contract development and manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome, at the time when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges. Together, we can bring your next medicine to life.

www.lonza.com/custom-manufacturing/small-molecule-technologies/highly-potent-api-hpapis.aspx

INNOVATION PARTNER

Cambrex

Cambrex is the leading small molecule company that provides drug substance, drug product and analytical services across the entire drug lifecycle. Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers' small molecule therapeutics into markets across the world.

- We put all of our energy and experience into being your partner of choice
- We create value for customers through manufacturing excellence, reliable quality and innovative science
- Our people are the experts that our customers enjoy working with

We truly offer our customers an end-to-end partnership for the research, development and manufacture of small molecule therapeutics at every stage of the drug lifecycle.

www.cambrex.com

INNOVATION PARTNER

Minakem

MINAKEM is a fully integrated development partner and commercial manufacturer for the global pharmaceutical companies.

- API manufacturing (Innovators/Generics and Highly Potent)
- Custom development (process development and optimization)
- Custom manufacturing
- Production of Key intermediates and building blocks

Minakem is a technology driven company with expertise in complex multi-steps synthesis, pressure chemistry, chiral synthesis, halogenation chemistry, steroid chemistry, high containment, controlled substances and "prazole" chemistry

www.minakem.com

INDUSTRY PARTNER

SafeBridge Consultants

SafeBridge Consultants, Inc. is the premier resource to the pharmaceutical and biotechnology industry in occupational health and safety. We have the capability to assist companies in developing the systematic approach to potent compound handling that helps speed products to market and reduce potential worker health effects from occurring.

www.safebridge.com

"Hanson Wade again managed to get a highly focused group of experts together . Information and networking was of high value."

Heraeus

"Great collection of relevant people & information in the industry."

SAFC

LET'S TALK

LIMITED PARTNERSHIP OPPORTUNITIES STILL AVAILABLE

Nathan Wilgoss
Partnerships Director
E: sponsor@hansonwade.com
T: +1 617 455 4188

READY TO REGISTER?

3 EASY WAYS TO BOOK

www.hpapi-summit.com

register@hansonwade.com

+1 617 455 4188

Package Details	Register & Pay by Friday, April 26	Standard Rate
Drug Developer Pricing		
Conference & 3 Workshops	**$2496** (save $500)	**$2696** (save $300)
Conference & 2 Workshops	**$2197** (save $400)	**$2397** (save $200)
Conference & 1 Workshop	**$1898** (save $300)	**$2098** (save $100)
Conference Only	**$1599** (save $200)	**$1799**
Workshop	**$399**	
Solution Provider Pricing		
Conference & 3 Workshops	**$4396** (save $500)	**$4596** (save $300)
Conference & 2 Workshops	**$3797** (save $400)	**$3997** (save $200)
Conference & 1 Workshop	**$3198** (save $300)	**$3398** (save $100)
Conference Only	**$2599** (save $200)	**$2799**
Workshop	**$699**	

"ENJOYED THE EVENT AND ALL THE SPEAKERS. GREAT FOR MEETING COLLEAGUES IN MANY AREAS"

Boehringer Ingelheim

Team Discounts -

3 Delegates:
10% Discount

4 Delegates:
15% Discount

5+ Delegates:
20% Discount

Please note that discounts are only valid when three or more delegates from one company **book and pay** at the same time.

***T&Cs APPLY**

VENUE

The Westin Waltham Boston
70 Third Avenue, Waltham
MA, 02451, USA

For further information or assistance, please visit www.marriott.co.uk

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH